A Randomised Controlled Trial of IFN-α, IL-2 and 5FU Versus IFN-α Alone in Metastatic Renal Cell Carcinoma (ISRCTN 46518965)*

By  

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 51-53

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite

Sunitinib malate for the treatment of renal cell carcinoma

By Wood Lori  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1323-1336

Informa Healthcare

Access to resources Recommend Favorite

REPEAT reaffirms the benefits of retreatment with PEG IFN-α-2a

By  

Inpharma, Vol. 1, Iss. 1524, 2006-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Onset of Male Gynaecomastia in a Patient Treated with Sunitinib for Metastatic Renal Cell Carcinoma

By Ballardini Pierluigi  

Clinical Drug Investigation, Vol. 29, Iss. 7, 2009-06 ,pp. : 487-490

Adis International

Access to resources Recommend Favorite